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1.1. NICE, audit and heart failure care
The national heart failure audit1 in England and Wales contin-
ues to grow and provides vital data for planning heart failure
services. The ﬁrst formal report relates to over 6000 patients
who were the ﬁrst 10 patients admitted with a primary diagno-
sis of heart failure each month to one of 86 hospitals contrib-
uting data in 2008–09. Most had left ventricular systolic
dysfunction, but an echocardiogram result was available in
only 75%. In-patient mortality was 12% and in survivors,
52 A.L. Clark80% were receiving an ACE inhibitor (or angiotensin receptor
blocker (ARB)), 50% a b blocker and 30% an aldosterone
antagonist at discharge.
The audit for 21,000 patients hospitalised with heart failure
in 2009–10 is also available.2 In-hospital mortality had fallen
slightly to 10.5%, but there was no dramatic change in drug
prescription rates. Some subsets of patients were particularly
likely to be actively treated (men aged 55–64, b blocker pre-
scription rate>70%), and others much less likely (women aged
>85, b blocker prescription rate 40%). Aldosterone antago-
nists were still prescribed for less than half the population.
Two striking features stand out from the data from both
audits. First, prescription rates vary greatly, with age––older
patients and women being less likely to be treated––and with
admission ward––patients admitted to cardiology wards being
much more likely to receive active treatment. Second, pharma-
cological treatment was better for patients admitted under car-
diologists, and so was survival. Although a minority of
patients admitted with heart failure is managed by cardiolo-
gists, the survival beneﬁt persists after correction for age and
sex (and other confounders).
The undertreatment of elderly patients with heart failure is
a particular cause for concern at a time when patients aged
>80 represent an increasing proportion of admissions for
heart failure.3 Treatment of older patients is hampered by their
associated comorbidities and polypharmacy and also by their
systematic exclusion from clinical trials, depriving doctors of
the evidence base they need to guide management decisions.4
Exclusion of the elderly by trial organisers shows no signs of
going away: among 251 trials recruiting patients in December
2008, more than 25% had an upper age limit for enrolment
and more than 80% excluded patients with comorbid
conditions.4
The National Institute for Health and Clinical Excellence
(NICE) has produced updated guidelines for heart failure
care.5,6 While there has been a lot of comment on the impor-
tance of measuring natriuretic peptides as an entry point to
heart failure care, NICE has also ﬁrmly recommended that
care led by a specialist in heart failure should be the norm. This
is true at assessment and diagnosis (a patient suspected of hav-
ing heart failure associated with a previous myocardial infarct
or with a very high natriuretic peptide level should receive
‘‘ . . .specialist assessment within 2 weeks’’) and during admis-
sion to hospital (‘‘when a patient is admitted to hospital be-
cause of heart failure, seek advice on their management plan
from a specialist in heart failure’’).
Such recommendations will impose new burdens. What is a
‘specialist’? NICE thinks it is ‘‘ . . .a doctor with subspeciality
interest in heart failure (often a consultant cardiologist) who
leads a specialist multidisciplinary heart failure team of profes-
sionals. . . ’’, but there are few such individuals available to take
up the responsibility. However a specialist is deﬁned, there is
no doubt that patients with heart failure fare better when cared
for by professionals with a particular interest in their condi-
tion. This is reﬂected in recent US data that have shown lower
mortality and readmissions for patients with heart failure man-
aged in high-volume compared with low-volume centres.7
One of the problems for a specialist heart failure service is
access to advanced treatments such as heart transplantation.
Transplantation in the UK is falling, partly owing to a fall
in the availability of donor organs,8 but just as important is
access to expert heart failure care.9 We have managed toreconﬁgure health services to provide primary angioplasty
for patients with acute myocardial infarction (MI) (including
for patients with non-ST elevation MI on rather ﬂimsy evi-
dence10). We should do so for patients with heart failure, for
whom reconﬁgured services will have a more far-reaching
beneﬁt.
1.2. Telemonitoring
An exciting possible advance in patient care is the use of re-
mote monitoring to guide changes in treatment. Typically,
automated devices in the home can measure weight, pulse rate
and heart rhythm and blood pressure and transmit the data to
a centre. Abnormal results then trigger patient contact with
possible change in treatment. Initial trials have suggested that
there may be beneﬁt from such systems, particularly when cou-
pled with telephone contact.11
A particular problem with telemonitoring is what to do
with the data. With a large number of patients potentially
transmitting quantities of data daily, the resource required to
deal with the data might become impossibly large. Attempts
to use automated systems have proved disappointing: in a
study of 1653 patients who had recently been hospitalised for
heart failure, which used telemonitoring with an interactive
voice-response system collecting daily information about
symptoms and weight, Chaudhry et al. found no impact on
re-admissions and mortality at 6 months.12 In another recent
study,13 remote monitoring did not improve outcomes among
710 patients randomised to remote monitoring using a system
that transmitted ECG, blood pressure and weight and included
a home emergency call system.
It is important to remember that telemonitoring itself does
not save lives or admissions, but that actions taken in response
to monitoring might do so. The reason recent trials have been
neutral may be that ‘usual care’ in these studies has progressed
to the point at which home monitoring can have little addi-
tional beneﬁcial effect and it may be that remote monitoring
is only likely to be helpful in people at particularly high risk.
It may be, too, that the variables measured are simply too
crude to be helpful guides to changing treatment.
Another approach to remote monitoring is to use implant-
able devices to measure haemodynamic changes invasively.
The Chronicle device allows pulmonary artery pressure to be
measured continuously and an early trial (COMPASS) sug-
gested that it might be helpful.14 A more promising technique,
perhaps, is the use of smaller devices implanted directly into the
pulmonary artery and communicating using acoustic wireless
communication.15 In the CHAMPION trial,16 550 patients
were randomised to have a CardioMEMS device or usual care.
The device was used to measure pulmonary artery pressure
once a day: it has no internal power source, but uses externally
applied radiofrequency energy. Its use was associated with a
30% reduction in the primary efﬁcacy end point of hospitalisa-
tion for heart failure at 6 months. It is not, of course, the
devices that improve outcome, but the changes in treatment
that follow from device readings. In COMPASS14 and CHAM-
PION,16 for example, patients with the device were receiving
higher doses of medication to treat heart failure.
The ﬁnal stage in the evolution of remotemonitoring is likely
to be to further empowerment of the patient. The devices can be
used to transmit data to the personmost concerned with the dis-
ease––the patient––who can then use the information to make
Almanac 2011: Heart failure. The national society journals present selected research that has driven 53daily changes to his or her treatment. In HOMEOSTASIS, 40
patients with severe heart failure were implanted with a device
measuring left atrial pressure and made changes to treatment
based on the readings using a preprogrammed hand-held pa-
tient advisor module.17 It is impossible to draw ﬁrm conclusions
from such a small observational study, but while diuretic treat-
ment fell as a result of the intervention, b blocker and ACE
inhibitor/ARB treatment increased. At the same time, mean left
atrial pressure fell and there did seem to be a reduction in clin-
ical events.
Invasive monitoring leads to an increase in prescription of
medical treatment for heart failure, which highlights another
nagging question: although we have clinical trial results to
guide us towards ‘target’ doses of, for example, b blockers
and ACE inhibitors, how are we to know how much is enough?
One possible guide is the use of natriuretic peptides: perhaps
treatment should continue to be increased until the natriuretic
peptide level is normal. Some small studies point in that direc-
tion, others do not: but there is evidence of publication bias in a
meta-analysis.18 A recent single-centre trial in 364 patients with
heart failure showed that treatment guided by N-terminal pro-
brain natriuretic peptide was associated with a 1-year mortality
identical to treatment guided by a clinical score.19 The ﬁnding
lends some weight to the argument against biomarker-guided
treatment but the question will only be resolved by a deﬁnitive
large trial.
2. Epidemiology
2.1. Heart failure with a normal ejection fraction
Heart failure with a normal ejection fraction (HeFNEF) re-
mains enigmatic. Epidemiology suggests that it is com-
mon,20,21 perhaps accounting for half of the cases of heart
failure. However, researchers recruiting patients to trials have
often found it extremely difﬁcult to identify suitable patients.
No clinical trial has as yet identiﬁed any successful treatment
for HeFNEF and some are sceptical of its existence as a single,
well-deﬁned entity.22,23 Problems arise because, at least in part,
breathlessness is very common in older people and because
some of the diastolic echocardiographic changes thought to
indicate that the heart is failing are simply consistent with
ageing.
One possibility that has been under-researched is that HeF-
NEF is more obviously a condition appreciated during exercise,
and echocardiographic measurements during exercise may
highlight diastolic abnormalities.24 An important observation
from a study of echocardiography and exercise of over 400 pa-
tients with possible HeFNEF25 was that very few––possibly as
few as 3%––actually had heart failure. Holland and colleagues25
emphasised the importance of measuring the ratio between E
and E0 as an index of left ventricular ﬁlling pressure, but others
have concentrated on much more subtle abnormalities of both
systole and diastole in patients with HeFNEF that worsen with
exertion.26 Impaired left atrial function during exercisemay also
contribute.27
While it remains a very active area of research, the cardinal
problem with HeFNEF and the main reason it has no (proven)
treatment is the absence of a satisfactory case deﬁnition. The
incorporation of natriuretic peptides into the diagnostic path-
way for HeFNEF should help as a raised level makes it morecertain that the heart is the cause of any symptom. However,
natriuretic peptides may show that there has been considerable
overdiagnosis of HeFNEF in the past. Potentially relevant in
this respect is the recent analysis of mode of death data from
I-Preserve: in patients with HeFNEF, death from heart failure
was surprisingly rare, the majority succumbing to other cardio-
vascular events.283. Treatment
3.1. Neurohormonal manipulation
ACE inhibitors, ARBs and b blockers, are of course, the main-
stays of medical treatment for patients with chronic heart fail-
ure. ACE inhibitors or ARBs should be given to all patients
with left ventricular systolic dysfunction, regardless of symp-
tom class, and there is general appreciation that the highest
tolerated dose should be used, side effects permitting. Evidence
for this approach comes from trials such as ATLAS,29 in which
patients randomised to higher-dose lisinopril fared better than
those receiving a lower dose.
There has been little evidence that a high-dose of ARBs is
better until the HEAAL study,30 in which 3846 patients with
heart failure and left ventricular ejection fraction <40% and
who were intolerant of ACE inhibitors were randomised to re-
ceive high-dose (150 mg) or low-dose (50 mg) daily losartan.
After a median 4.7 years’ follow-up there was a lower rate of
deaths or hospitalisation for heart failure in the high-dose group
(HR= 0.90, 95% CI 0.82–0.99; p= 0.027). Thus it does thus
seem that up-titrating of ARB doses confers clinical beneﬁt.
With RALES31 (spironolactone) and EPHESUS32 (eplere-
none), aldosterone blockade has also become important, with
the proviso that aldosterone blockade has not been shown to
be beneﬁcial in patients with mild heart failure, at least until
recently. In EMPHASIS-HF,33 2737 patients with heart failure
due to systolic dysfunction and New York Heart Association
(NYHA) class II symptoms were randomised to eplerenone
(up to 50 mg daily) or placebo, in addition to standard
treatment. There was a 37% reduction in the risk of the pri-
mary end point (cardiovascular death or hospitalisation for
heart failure) in the eplerenone group, at the cost of a small in-
crease in the risk of hyperkalaemia. It seems likely that guide-
line groups will now recommend the use of eplerenone in all
those with heart failure due to left ventricular systolic
dysfunction.
A problem with the more widespread use of aldosterone
antagonists is that the risk of life-threatening hyperkalaemia
may increase. Certainly after the RALES report, there was a ra-
pid uptake of spironolactone usage resulting in a marked in-
crease in morbidity and mortality from hyperkalaemia.34 A
possible approach to preventing hyperkalaemia is to use potas-
sium-binding resins. In PEARL-HF,35 105 patients with heart
failure and a history of hyperkalaemia which had interfered
with medical treatment, or who had chronic kidney disease,
were recruited. The potassium binder, RLY5016, was given in
addition to spironolactone and led to a marked reduction in
the risk of hyperkalaemia compared with placebo (7.3% vs
24.5%, p= 0.015); and a higher proportion of patients reach-
ing spironolactone 50 mg/day (91% vs 74%, p= 0.019). These
are encouraging data, but lead to the obvious unanswered
54 A.L. Clarkquestion: to what extent is the beneﬁt of aldosterone antago-
nism mediated by hyperkalaemia? If the answer is ‘most’, or
‘all’, then potassium-binding may not have much to offer.
3.2. Ivabradine
The mechanism by which b blockers mediate their beneﬁcial
effects is not clear, but has long been thought to be related
to their ability to reduce heart rate.36,37 Ivabradine reduces
heart rate by reducing sinus node discharge rate while having
no other haemodynamic effect and might thus both test the
heart rate hypothesis and provide an alternative for patients
intolerant of b blockers.
In SHIFT,38 6558 patients with heart failure and a low ejec-
tion fraction and who were in sinus rhythm with a heart rate of
at least 70 beats/min were randomised to receive ivabradine or
placebo in addition to usual treatment (including b blocker,
where tolerated). Ivabradine was associated with an 18%
reduction in the primary end point (cardiovascular death or
hospital admission for worsening heart failure), driven mainly
by a reduction in hospital admission.
The ﬁndings of SHIFT have been much discussed. It is
important to point out that the beneﬁts of ivabradine were
much more striking in those with a higher resting heart
rate,38,39 and that although around 90% of patients were tak-
ing a b blocker at baseline, only 23% were taking a target dose,
only 49% were receivingP50% of a target dose and 16% were
receiving a b blocker not shown to be beneﬁcial.
The SHIFT ﬁndings do suggest that there is a role for
ivabradine in patients with chronic heart failure, but it is not
a substitute for b blocker use. There is an enormous body of
evidence supporting the use of b blockers, which improves
mortality as well as hospitalisation. Ivabradine should be
considered only in those patients who still have a resting heart
rate above 70 despite maximally tolerated doses of b blockers
(or perhaps used in patients truly intolerant of b blockers).
Data from ‘real-world’ populations of patients with heart
failure suggest that the proportion of patients who might be
eligible is low, perhaps around 5%.40
3.3. Iron
Is iron deﬁciency a target for treatment? Anaemia is very com-
mon in patients with heart failure,41 but iron deﬁciency with-
out anaemia is also common. The best way to manage iron
deﬁciency is not clear: oral iron treatment is widely believed
to be ineffective, yet intravenous iron treatment is also thought
to be difﬁcult or dangerous. However, a new generation of
intravenous iron preparations is now available which allows
both rapid and safe administration of iron to patients.
Some preliminary studies suggested that intravenous iron
repletion might lead to an improvement in exercise capacity,42
and the FAIR-HF study was designed to see if iron might be
beneﬁcial in a larger group of patients.43 Four hundred and
ﬁfty-nine patients were randomised 2:1 to receive iron or pla-
cebo infusions (with only the patient blind to treatment). After
6 months, there was an improvement in patient self-reported
global assessment (50% ‘much or moderately improved’, com-
pared with 28% of patients in the placebo group) as well as in
secondary end points, including distance covered in a 6 min
walk test (about 40 m increase compared with no changein the placebo group). There were similar improvements
regardless of starting haemoglobin.
The results have to be treated with some caution: FAIR-HF
was not a large trial, blinding was difﬁcult and the end points
were to a varying degree subjective. Nevertheless, iron treat-
ment appeared safe and is now an option for patients who re-
main symptomatic despite medical treatment. An absolutely
essential question to answer, though, is the extent to which pa-
tients with heart failure should be further investigated for an
underlying cause for any iron deﬁciency, a question not dealt
with by FAIR-HF.
Another possible approach for correcting anaemia in heart
failure is the use of erythropoiesis-stimulating proteins. A
meta-analysis of six randomised controlled trials found that
treatment was associated with a signiﬁcantly lower risk of hos-
pitalisation compared with placebo.44 Mortality was unaf-
fected. These outcomes are in contrast with studies in cancer
and kidney disease and prompted the authors to a call for a
large phase III morbidity and mortality trial of anaemia cor-
rection with erythropoiesis-stimulating proteins in patients
with chronic heart failure.
3.4. Metabolic manipulation
The energy-generating processes of the failing cardiac myocyte
are abnormal. Some investigators have focused on substrate
use: fatty acid metabolism produces a lower yield of ATP for
each molecule of oxygen consumed than glucose metabolism
(although fatty acid oxidation yields more ATP per mole) and
so it makes sense to try to switch metabolism from fatty acids
to glucose.45
Various approaches have been tried: perhexiline, for exam-
ple, blocks mitochondrial free fatty acid uptake by inhibiting
carnitine palmitoyltransferase. In a small study, perhexiline
led to improvements in exercise capacity and left ventricular
function and more rapid recovery of phosphocreatine after
exercise.46 Trimetazidine inhibits lipid b-oxidation and its use
has been associated with both an increase in left ventricular
ejection fraction and reduction in resting energy expenditure
(known to be high in heart failure).47 A meta-analysis of the
available data for trimetazidine48 even suggests that its use
might improve mortality and it is surely time for a large-scale
trial of metabolic modulators.
3.5. Cardiac resynchronisation therapy
Cardiac resynchronisation therapy (CRT: or biventricular pac-
ing) is one of the most exciting new developments for patients
with chronic heart failure and left bundle branch block
(LBBB) introduced in recent years. Particularly important is
its effect on reducing mortality,49 but around two-thirds of pa-
tients get marked symptomatic beneﬁt from their devices.50
That one-third do not has led to the concept of the ‘non-
responder’ to CRT. How to deﬁne ‘non-response’ varies from
paper to paper, with some using symptomatic criteria and oth-
ers using measures of left ventricular function. What has
proved difﬁcult to answer is whether ‘non-response’ is related
to lack of mortality beneﬁt.
A great deal of time and effort has been expended on trying
to identify which patients might beneﬁt from CRT. The sever-
ity of symptoms does not seem to matter greatly: those with
Almanac 2011: Heart failure. The national society journals present selected research that has driven 55modest symptoms appear to gain as much mortality beneﬁt as
those with worse NYHA class of symptoms.51 In MADIT-
CRT,52 1820 patients with NYHA class I or II symptoms
and LBBB were randomised 2:1 to receive CRT (or not) in
addition to a deﬁbrillator. There was a 34% reduction in the
risk of death or a heart failure event (deﬁned as congestion
treated either with intravenous treatment (diuretics, nesiritide
or inotrope) for more than 2 h, regardless of the setting, or:
with an increased heart failure regimen during formal hospital
admission). The reduction in risk was driven by a reduction in
heart failure events. In RAFT,53 which included 1438 patients
with mild (NYHA class II) symptoms, CRT added to a deﬁ-
brillator led to a reduction in the rate of death and hospitali-
sation for heart failure.
Another possible selection criterion is the presence of dys-
synchrony on some form of cardiac imaging. Underlying this
approach is the assumption that CRT works by improving
ventricular coordination, which in turn must in some way be
measurable. However, of the large, randomised trials showing
a mortality beneﬁt for CRT, none used measures of dyssyn-
chrony as an entry criterion other than a minority of patients
in CARE-HF. Vigorous efforts to prove the robustness of any
of the very many potential measures of dyssynchrony have
failed thus far, with the PROSPECT study of nearly 500 pa-
tients being the largest available set of data.54 There was poor
reproducibility of the measures, none of which related strongly
to the assessment of response.
The only selection criteria consistently shown to be related
to outcome are electrocardiographic. It is a commonplace
observation that the mean QRS duration in the mortality trials
of CRT was around 150 ms and where it has been analysed,
the broader the QRS, the greater the beneﬁt. Subgroup analy-
sis of PROSPECT showed some symptomatic beneﬁt for CRT
in patients with mechanical dyssynchrony and a narrow QRS
complex55 and similar ﬁndings have been reported in small sin-
gle-centre trials.56 There is no doubt, however, that the beneﬁts
of CRT are largely conﬁned to patients with left bundle branch
block,53 and it may even be that beneﬁt is restricted to those
with a QRS >150 ms.57
Similarly, while small non-randomised studies have re-
ported variable beneﬁt of CRT for patients in atrial ﬁbrillation
(AF), there is almost no evidence to support the practice from
randomised trials.58 The few trials that included patients in AF
showed no beneﬁt with CRT.53 Although the European Soci-
ety of cardiology guideline updates suggest that CRT might
be considered in patients in AF,59 the class of recommendation
was only IIa, level B or C.
What should all this mean in practice? CRT should cer-
tainly be considered for all patients with left ventricular sys-
tolic dysfunction and symptomatic heart failure who are in
sinus rhythm and have left bundle branch block. CRT might
be tried for those patients with intractable symptoms and
AF (and left bundle branch block), but only if the ventricular
rate is well controlled to maximise pacing. Better still, restora-
tion of sinus rhythm in such patients may improve both the
quality of life and LV function60 while ensuring a more favour-
able response to CRT.
A more far-reaching question is whether patients with a
standard bradycardia pacing indication would beneﬁt from
biventricular pacing. A small study using echocardiographic
end points suggested that biventricular pacing was associated
with less deterioration in left ventricular function,61 butwhether widespread use of biventricular pacing is indicated
will have to await the outcome of larger outcome studies.3.6. Exercise training
The case for exercise training as a standard part of the man-
agement of patients with chronic heart failure has been build-
ing over several years.62 Training undoubtedly improves
patients’ symptoms and several of the predictors of an adverse
prognosis.63 Mounting a properly powered survival study has
proved difﬁcult, not least because of the problems of blinding
and the difﬁculty of cross-overs.
The HF-ACTION study managed to recruit 2331 patients
randomised to usual care or an intensive training regimen (36
supervised 30 min sessions three times a week, followed by
home exercise ﬁve times a week at moderate intensity for
40 min).64 Although the primary end point of all-cause mortal-
ity and hospitalisation was no different between the two groups
at a median follow-up of 30 months, there was a signal that
training might be beneﬁcial as after adjustment for baseline dif-
ferences in predictors of outcome, training was associated with
an 11% reduction in the primary end point. More importantly,
perhaps, training was associated with a marked improvement
in the quality of life, which appeared early during the interven-
tion and continued throughout the course of the study.65
It is still unclear whether the type of training stimulus is
important: most evidence relates to aerobic training. A recent
systematic review of trials of resistance training found that the
quality of the studies has been poor and effects were inconclu-
sive for quality-of-life outcomes.66
Incorporating exercise training into standard heart failure
management is difﬁcult.62 Compliance will always be a chal-
lenge––even in HF-ACTION, and after a year, patients’ com-
pliance with exercise was only about 80%. Although home
exercise is safe,64 initial supervision may be helpful for both
patients and their carers and the resource implications are sub-
stantial. Whether a training programme is possible for many
patients, who may be elderly, frail and have multiple comor-
bidities, is debatable. Nevertheless, patients can be reassured
that exercise is safe and will improve their symptoms.3.7. Revascularisation
The commonest cause of heart failure is underlying ischaemic
heart disease. However, there is no good evidence that treat-
ments directed at ischaemia with, for example, statins,67 are
beneﬁcial, despite the intuitive feeling that treating ischaemia
should be effective. One of the more challenging questions
has been whether revascularisation for patients with heart fail-
ure and no angina might be beneﬁcial. Observational studies
suggest that revascularisation might indeed improve prognosis,
particularly in those with demonstrable viability on functional
testing,68 but we now have two randomised trials that examine
the problem directly.
In HEART,69 patients with heart failure and viable but dys-
functional myocardium were randomised to two strategies of
care: conservative management or angiography with a view
to revascularisation. There was no difference in survival be-
tween the two groups at 59 months. Although the trial re-
cruited slowly and only 138 of the planned 800 patients were
enrolled, there was no signal suggesting beneﬁt.
56 A.L. ClarkSTICH70 included 1212 patients with an ejection fraction
635% who were considered suitable for coronary artery
bypass grafting (CABG). The patients were randomised to
CABG or continued medical treatment. Over a median fol-
low-up of 56 months, there was no difference in all-cause mor-
tality, the primary end point, between the treatment groups.
The combined end point of all-cause mortality and cardiovas-
cular hospitalisation was reduced in the CABG group, but the
analysis excludes hospitalisation for the original operation,
which is scarcely a negligible event: the 60 hospitalisations pre-
vented by CABG required 555 hospitalisations for the CABG
procedure itself.71 There were more deaths in the CABG group
for more than 2 years after randomisation, emphasising that
this is not a benign intervention.
Together, HEART and STICH show that there is, at most,
a marginal beneﬁt for revascularisation in patients with heart
failure and underlying ischaemic heart disease. How the results
relate to clinical practice is not clear: in STICH, the average
age of patients was around 60, resting heart rate was >70 (sug-
gesting, perhaps, inadequate b blockade) and fewer than 10%
had ‘chronic renal insufﬁciency’ (creatinine is not reported in
the paper). Despite the enormous effort expended to answer
the question, it is still not clear whether revascularisation is
helpful for patients with heart failure.
3.8. Acute heart failure
After many years of clinical trials in patients with chronic
heart failure, there has been renewed interest in the problem
of acute heart failure––in part, driven by the availability of
new drugs as potential treatments.
One of the most widely used new treatments for acute heart
failure has been nesiritide, licensed for use in the USA, largely
as a result of trials showing some improvement in haemody-
namics.72 It has always seemed a little strange from a
European perspective that nesiritide has been so widely used
and the European Medicines Agency did not allow its use in
the EU. A 7000 patient trial comparing nesiritide with placebo
in addition to standard treatment has now been completed.73
No statistically signiﬁcant difference in symptoms scores was
found between the two groups, or in rehospitalisation or death
at 30 days.
Another agent for possible use in patents with acute heart
failure is rolofylline, an adenosine antagonist. Rolofylline
might help to prevent decline in renal function with diuretic
treatment by interrupting glomerulotubular feedback. How-
ever, in a 2000 patient study, rolofylline had no effect on the
primary end point (a composite ‘treatment success’ score), re-
nal function or mortality.74,75
Taken together, the trials of rolofylline and nesiritide high-
light the importance of using clinical trials appropriately to
drive the evolution of treatment. Reliance on relatively small
trials with inappropriate end points led to the nesiritide debaˆ-
cle, whereas investigation of rolofylline followed an appropri-
ate sequence with early small-scale studies informing the
design of a properly powered endpoint study.
The correct diuretic dosing regimen for patients admitted
with ﬂuid retention has often been a controversial question
and the DOSE trial76 was designed to help guide this aspect
of acute heart failure management. Three hundred and eight
patients with ﬂuid retention due to heart failure were random-
ised to receive furosemide either as a bolus every 12 h or bycontinuous infusion: both were given as either low or high
dose. There were two co-primary end points: patients’ global
symptom assessment over 72 h and change in creatinine level
from baseline to 72 h.
No signiﬁcant difference was found between bolus
and infusion regimens, but a small (and statistically non-
signiﬁcant) greater improvement in symptoms in the high-dose
versus low-dose groups was seen. The high-dose groups had a
substantially greater diuresis.
It can be difﬁcult directly to compare practice in the USA
with Europe. Typically, patients with acute heart failure are
in hospital for around 5 days in the USA, but 11 days in Europe
and any acute weight loss during admission (presumably
reﬂecting ﬂuid loss) is very much smaller, implying that patients
are admitted in the USA with very much less ﬂuid overload
than in Europe. Whether there are differences between furose-
mide given by bolus or continuous infusion over a longer time
scale cannot be addressed by DOSE, but the message that high
doses of furosemide (deﬁned here as 2.5 times the patient’s
usual oral dose) cause a greater diuresis is clear.References
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